Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives

MLA

Tanaka Y, et al. “Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives.” Patient Preference and Adherence, vol. ume 17, Oct. 2023, pp. 2499–516. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.9594c86dc3104ac2900c1aaa0941c974&authtype=sso&custid=ns315887.

APA

Tanaka Y, Genovese MC, & Matsushima H. (2023). Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives. Patient Preference and Adherence, ume 17, 2499–2516.

Chicago

Tanaka Y, Genovese MC, and Matsushima H. 2023. “Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives.” Patient Preference and Adherence ume 17 (October): 2499–2516. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.9594c86dc3104ac2900c1aaa0941c974&authtype=sso&custid=ns315887.